

Could the SARS-CoV-2 Infection be Acquired via the Eye?

Siukan Law^{1*}, Ali Hassan A Alnasser², Albert Wingnang Leung³, Chuanshan Xu⁴ and Jaffar A. Al-Tawfiq⁵

¹Department of Science, School of Science and Technology, Hong Kong Metropolitan University, Hong Kong, China

²Department of Laboratory, Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia

³School of Nursing, Tung Wah College, Hong Kong, China

⁴Key Laboratory of Molecular Target and Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China

⁵Specialty Internal Medicine and Quality Department, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Indiana University School of Medicine, Indianapolis, Indiana, USA; Johns Hopkins University School of Medicine, Baltimore, USA

ARTICLE INFO

Article history:

Received: 19 April 2021

Accepted: 25 April 2021

ONLINE:

DOI 10.5001/omj.2021.121

Dear Editor,

The COVID-19 outbreak was first identified in the Hubei province of Wuhan, China, in December 2019. It is caused by SARS-CoV-2. The proposed transmission of SARS-CoV-2 is respiratory droplets < 5 µm in diameter or by indirect or direct human-to-human contact.¹ SARS-CoV-2 may also be transmitted through the eyes. The receptor for SARS-CoV-2 is angiotensin-converting enzyme 2 (ACE-2). SARS-CoV-2 replicates at the binding site on the surface of target cells, such as ocular tissues, leading to the cleavage of the ACE-2 receptor, activation of the spike protein, and inflammation in the form of ocular manifestations such as conjunctivitis, anterior uveitis, retinitis, and optic neuritis. SARS-CoV-2 can cause eye manifestation.² ACE-2 is expressed by conjunctival epithelial cells, and the presence of ACE-2 is significantly elevated in conjunctival cells for patients with conjunctivitis, conjunctival nevi, conjunctival papilloma, conjunctival cysts, and conjunctival polyps' epithelial cells compared to control subjects.³

It has been reported that ocular surface cells were potential infection sites of SARS-CoV-2. The proteases of ocular surface cells facilitate the binding of SARS-CoV-2 on the viral spike protein to the ACE-2 receptor in the conjunctiva, limbus, and cornea. SARS-CoV-2 might exist in tears since there was an expression of ACE-2 on the transmembrane

serine protease 2 (TMPRSS2).⁴ Another study found that SARS-CoV-2 was present on conjunctiva swabs from two out of 11 (18.2%) patients tested for SARS-CoV-2 via nasopharyngeal swabs. A common symptom was conjunctivitis, and SARS-CoV-2 could be transmitted by aerosol contact with the conjunctiva.⁵

However, the risk of SARS-CoV-2 transmission through tears was low. In a study of 17 patients, none of the 32 patient tear samples was positive for SARS-CoV-2.⁶ The replication of SARS-CoV-2 was much more efficient than that of SARS-CoV in human conjunctiva and the upper respiratory airways. Thus, eyes could be a potential route of SARS-CoV-2 transmission.⁷

All of the above information demonstrates that SARS-CoV-2 might be acquired through the eyes, wearing a face shield could benefit, especially during aerosol-generating procedures.

REFERENCES

1. Peng PW, Ho PL, Hota SS. Outbreak of a new coronavirus: what anaesthetists should know. *Br J Anaesth* 2020 May;124(5):497-501.
2. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. *Ocul Immunol Inflamm* 2020 Apr;28(3):391-395.
3. Li S, Li D, Fang J, Liu Q, Sun X, Xu G, et al. COVID-19 receptor ACE2 is expressed in human conjunctival tissue, especially in diseased conjunctival tissue. *MedRxiv* 2020.

4. Zhou L, Xu Z, Castiglione GM, Soiberman US, Eberhart CG, Duh EJ. ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. *Ocul Surf* 2020 Oct;18(4):537-544.
5. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. *JAMA Ophthalmol* 2020 May;138(5):575-578.
6. Seah IY, Anderson DE, Kang AE, Wang L, Rao P, Young BE, et al. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. *Ophthalmology* 2020 Jul;127(7):977-979.
7. Hui KP, Cheung MC, Perera RA, Ng KC, Bui CH, Ho JC, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. *Lancet Respir Med* 2020 Jul;8(7):687-695.